Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG Somatropin (Jintrolong) Dose-Control Study in Children with GHD
NCT02908958Phase 4Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of peg-somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Change of Height Standard Deviation Score for Chronological Age at 26 weeks. Status: unknown.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02908958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908958.